AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

PTC Therapeutics Inc. (PTCT)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

49.67

-2.15 (-4.15%)

At close: Feb 18, 2025, 3:59 PM

49.44

-0.46%

After-hours: Feb 18, 2025, 04:42 PM EST

undefined% (undefined)

Bid	48.1
Market Cap	3.83B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-5.94
PE Ratio (ttm)	-8.36
Forward PE	n/a
Analyst	Buy

Ask	52.57
Volume	542,903
Avg. Volume (20D)	739,323
Open	52.07
Previous Close	51.82
Day's Range	49.53 - 52.95
52-Week Range	24.00 - 54.16
Beta	undefined

About PTCT

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offer...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 20, 2013

Employees 988

Stock Exchange NASDAQ

Ticker Symbol PTCT

Website https://www.ptcbio.com

Full Company Profile

Analyst Forecast

According to 13 analyst ratings, the average rating for PTCT stock is "Buy." The 12-month stock price forecast is $59, which is an increase of 18.78% from the latest price.

Buy 61.54%

Hold 15.38%

Sell 23.08%

Stock Forecasts

Next Earnings Release

PTC Therapeutics Inc. is scheduled to release its earnings on Feb 27, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 weeks ago

+9%

PTC Therapeutics shares are trading higher after C... Unlock content with Pro Subscription

2 months ago

+18.66%

PTC Therapeutics shares are trading higher after the company announced it signed a global licensee and collaboration agreement with Novartis for its PTC518 Huntington's Disease program.

News

2 weeks ago · zacks.com

PTC Therapeutics (PTCT) Moves 9.0% Higher: Will This Strength Last?

PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price inc...

2 months ago · zacks.com

PTCT Stock Soars on Licensing Deal With NVS for Huntington's Therapy

Per the terms, PTC will receive $1 billion in upfront payment from Novartis upon the deal's closure. It is also eligible for milestone payments of up to $1.9 billion.

2 months ago · https://thefly.com

PTC Therapeutics price target raised to $56 from $45 at Barclays

Barclays raised the firm's price target on PTC Therapeutics to $56 from $45 and keeps an Equal Weight rating on the shares. The company's deal with Novartis is favorable with high upfront payment and ...

2 months ago · investopedia.com

PTC Therapeutics Stock Soars on Novartis Licensing Agreement

Shares of PTC Therapeutics (PTCT) soared 16% Monday when the pharmaceutical firm announced it struck a nearly $2 billion license and collaboration deal with Novartis (NVS).

2 months ago · benzinga.com

PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program

On Monday, PTC Therapeutics, Inc. PTCT signed an exclusive global license and collaboration agreement with Novartis AG NVS for its PTC518 Huntington's disease program, which includes related molecule...

2 months ago · investors.com

PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone

Novartis will pay PTC Therapeutics up to $2.9 billion in a licensing deal for its Huntington's treatment. PTC Therapeutics stock surged.

2 months ago · reuters.com

PTC Therapeutics signs up to $1.9 billion licensing deal with Novartis

PTC Therapeutics has entered into a licensing deal with a unit of Novartis AG for up to $1.9 billion, the company said on Monday, for its experimental drug being developed for a rare neurological diso...

2 months ago · benzinga.com

PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, Huntington's Programs

On Tuesday, PTC Therapeutics Inc PTCT revealed data from the global Phase 2 placebo-controlled CardinALS study of Utreloxastat in amyotrophic lateral sclerosis patients.

2 months ago · reuters.com

PTC Therapeutics discontinues development of ALS drug after trial failure

PTC Therapeutics said on Tuesday it is discontinuing the development of its drug for a type of fatal neurodegenerative disease, as it did not meet the main goal in a mid-stage trial.